Matches in Nanopublications for { ?s ?p "[The veliparib and CPT-11 combination can be further explored as a treatment of metastatic castration-resistant prostate cancers that have frequent p53 mutations and enriched genomic instability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP947047.RAQGGcr88-cDJmkKjpYfFlJY8gTv73mfIELBZNE9wj_GI130_assertion description "[The veliparib and CPT-11 combination can be further explored as a treatment of metastatic castration-resistant prostate cancers that have frequent p53 mutations and enriched genomic instability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP947047.RAQGGcr88-cDJmkKjpYfFlJY8gTv73mfIELBZNE9wj_GI130_provenance.
- NP1163696.RAWsBUx5RYHeOOHMqcsGfimHHJ1uTGb5qDJbZr7TjyO80130_assertion description "[The veliparib and CPT-11 combination can be further explored as a treatment of metastatic castration-resistant prostate cancers that have frequent p53 mutations and enriched genomic instability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1163696.RAWsBUx5RYHeOOHMqcsGfimHHJ1uTGb5qDJbZr7TjyO80130_provenance.
- assertion description "[The veliparib and CPT-11 combination can be further explored as a treatment of metastatic castration-resistant prostate cancers that have frequent p53 mutations and enriched genomic instability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The veliparib and CPT-11 combination can be further explored as a treatment of metastatic castration-resistant prostate cancers that have frequent p53 mutations and enriched genomic instability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP925948.RAkymDrNRSXUUErOrhtv5cSOMAusSXAAJmGUmVZUv4ntw130_assertion description "[The veliparib and CPT-11 combination can be further explored as a treatment of metastatic castration-resistant prostate cancers that have frequent p53 mutations and enriched genomic instability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925948.RAkymDrNRSXUUErOrhtv5cSOMAusSXAAJmGUmVZUv4ntw130_provenance.
- NP1163693.RAjInX4ie3Bicvu_lKS0GeDFX8HX9dFkmeJ19DRRDwbsY130_assertion description "[The veliparib and CPT-11 combination can be further explored as a treatment of metastatic castration-resistant prostate cancers that have frequent p53 mutations and enriched genomic instability.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1163693.RAjInX4ie3Bicvu_lKS0GeDFX8HX9dFkmeJ19DRRDwbsY130_provenance.